[1]刘旭阳 孙玉芳 汤舒洁 项涛.血清hsa-miR3173-5p和hsa-miR-4297作为心源性脑卒中诊断标志物的研究[J].心血管病学进展,2024,(5):470.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.019]
　LIU Xuyang,SUN Yufang,TANG Shujie,et al.Serum hsa-miR3173-5p and hsa-miR-4297 as Diagnostic Markers of Cardiogenic Stroke[J].Advances in Cardiovascular Diseases,2024,(5):470.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.019]
点击复制

血清hsa-miR3173-5p和hsa-miR-4297作为心源性脑卒中诊断标志物的研究()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年5期
页码:
470
栏目:
论著
出版日期:
2024-05-25

文章信息/Info

Title:
Serum hsa-miR3173-5p and hsa-miR-4297 as Diagnostic Markers of Cardiogenic Stroke
作者:
刘旭阳 孙玉芳 汤舒洁 项涛
?西南交通大学附属医院 成都市第三人民医院急诊科,四川 成都 610031)
Author(s):
LIU Xuyang; SUN Yufang; TANG Shujie; XIANG Tao
(Department of Emergency,The Affiliated Hospital of Southwest Jiaotong University,The Third Peoples Hospital of Chengdu,Chengdu 6 10031,Sichuan,China)
关键词:
心源性脑卒中; miRNA; 诊断标志物
Keywords:
Cardiogenic stroke ; miRNA; Diagnostic marker
DOI:
10.16806/j.cnki.issn.1004-3934.2024.05.019
摘要:
目的 研究血清hsa-miR3173-5p和hsa-miR-4297与心源性脑卒中的关联性，及其作为诊断标志物的可行性。方法 GEO数据库整合分析筛选出可能的心源性脑卒中特异性miRNA（hsa-miR3173-5p和hsa-miR-4297），通过孟德尔随机化与共定位分析验证两个miRNA对心源性脑卒中发病的危险作用，并对它们在miRNA-mRNA调控网络中的靶基因进行富集分析来寻找相关通路。纳入2022年3月—2023年1月于成都市第三人民医院急诊科诊断新发缺血性脑卒中的患者共103例，其中心源性脑卒中22例（病例组），非心源性脑卒中81例（对照组）。采用实时定量聚合酶链反应检测血清hsa-miR3173-5p和hsa-miR-4297的表达水平，多因素逻辑回归分析其与心源性脑卒中的相关性，采用ROC曲线评估预测价值。结果 孟德尔随机化分析提示遗传预测的循环血液中hsa-miR3173-5p和hsa-miR-4297表达增高分别使心源性脑卒中的发病风险增加46%和70%。共定位分析提示循环血液中hsa-miR3173-5p和hsa-miR-4297的表达与心源性脑卒中存在共享遗传变异的概率分别为95%和86%。病例组血清hsa-miR3173-5p和hsa-miR-4297表达水平显著高于对照组（P＜0.05），hsa-miR3173-5p（OR=6.30，95% CI 1.79～22.14，P=0.004）和hsa-miR-4297（OR=12.38，95% CI 1.97～77.72，P=0.007）与心源性脑卒中有显著关联。hsa-miR3173-5p和hsa-miR-4297的ROC曲线下面积（AUC）分别为0.705和0.624，将hsa-miR3173-5p和hsa-miR-4297联合房颤共同进行分析，其AUC为0.842。结论 hsa-miR3173-5p和hsa-miR-4297的表达水平与心源性脑卒中具有密切关联，有望作为心源性脑卒中的诊断标志物。
Abstract:
Objective To explore the levels of serum hsa-miR3173-5p and has-miR-4297 and their feasibility as the diagnostic markers in cardiogenic stroke. Methods GEO database integration analysis screened out possible cardiogenic stroke-specific miRNAs (hsa-miR3173-5p and hsa-miR-4297),verified the risk role of the two miRNAs in the development of cardiogenic stroke by Mendelian randomisation and c olocalization analysis,and their target genes in the miRNA-mRNA regulatory network were enriched to search for related pathways. A total of 103 new ischemic stroke patients diagnosed in the emergency department from March 2022 to January 2023 were included,among which 22 cases were cardiogenic stroke (case group) and 81 were non- cardiogenic stroke (control group). The expression levels of serum hsa-miR3173-5p and hsa-miR-4297 were detected by real-time quantitative polymerase chain reaction ,and their correlation with cardiogenic stroke was analyzed by multivariable logistic regression. The predictive value was evaluated using the receiver operating characteristic (ROC) curve. Results Mendelian randomisation analysis suggested that genetically predicted increased expression of hsa-miR3173-5p and hsa-miR-4297 in circulating blood increased the risk of cardiogenic stroke by 46% and 70% ,respectively. Colocalization analysis suggested that the expression of hsa-miR3173-5p and hsa-miR-4297 with cardiogenic stroke was 95% and 86% ,respectively. The expression levels of serum hsa-miR3173-5p and hsa-miR-4297 in the case group were significantly higher than in the control group (P<0.05),and hsa-miR3173-5p(OR=6.30,95% CI 1.79～22.14, P=0.004) and hsa-miR-4297 (OR=12.38,95% CI 1.97～77.72, P=0.007) were significantly associated with cardiogenic stroke . The area under the ROC curve (AUC) for hsa-miR3173-5p and hsa-miR-4297 were 0.705 and 0.624 respectively,and the AUC of the combined analysis of hsa-miR3173-5p and hsa-miR-4297 with atrial fibrillation is 0.842. Conclusion The expression levels of hsa-miR3173-5p and hsa-miR-4297 are closely related to cardiogenicc stroke,and are promising as diagnostic markers for cardiogenic stroke

参考文献/References:

[1]GBD 2016 DALYs and HALE Collaborators. Global,regional,and national disability-adjusted life-years(DALYs) for 333 diseases and injuries and healthy life expectancy(HALE) for 195 countries and territories,1990—2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet,2017,390(10100):1260-1344.

[2]Wu S,Wu B,Liu M,et al. Stroke in China:advances and challenges in epidemiology,prevention,and management[J]. Lancet Neurol,2019,18(4):394-405.

[3]Wolf ME,Sauer T,Alonso A,et al. Comparison of the new ASCO classification with the TOAST classification in a population with acute ischemic stroke[J]. J Neurol,2012,259(7):1284-1289.

[4]O’Carroll CB,Barrett KM. Cardioembolic stroke[J]. Continuum(Minneap Minn),2017,23(1,Cerebrovascular Disease):111-132.

[5]Yu L,Zheng Y,Ju B,et al. Research progress of miRNA-disease association prediction and comparison of related algorithms[J]. Brief Bioinform,2022,23(3):bbac066.

[6]Kwah LK,Diong J. National Institutes of Health Stroke Scale(NIHSS)[J].?J Physiother,2014,60(1):61.

[7]中华医学会老年医学分会老年神经病学组,心源性卒中诊断中国专家共识撰写组. 心源性卒中诊断中国专家共识(2020)[J]. 中华老年医学杂志,2020,39(12):1369-1378.

[8]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682.

[9]Bjerkreim AT,Khanevski AN,Thomassen L,et al. Five-year readmission and mortality differ by ischemic stroke subtype[J]. J Neurol Sci,2019,403:31-37.

[10]Kelley RE,Kelley BP. Heart-brain relationship in stroke[J].?Biomedicines,2021,9(12):1835.

[11]Fan ZX,Liu RX,Liu GZ. Development and refinement of diagnostic and therapeutic strategies for managing patients with cardiogenic stroke:an arduous journey[J].?World J Clin Cases,2023,11(4):719-724.

[12]Bogiatzi C,Hackam DG,McLeod AI,et al. Secular trends in ischemic stroke subtypes and stroke risk factors[J].?Stroke,2014,45(11):3208-3213.

[13]Wu Z,Zhao M,He M,et al. Validation of the use of B-type natriuretic peptide point-of-care test platform in preliminary recognition of cardioembolic stroke patients in the ED[J]. Am J Emerg Med,2015,33(4):521-526.

[14]Zeng X,Zhang X,Zou Q. Integrative approaches for predicting microRNA function and prioritizing disease-related microRNA using biological interaction networks[J].?Brief Bioinform,2016,17(2):193-203.

[15]Vidigal JA,Ventura A. The biological functions of miRNAs:lessons from in vivo studies[J].?Trends Cell Biol,2015,25(3):137-147.

[16]Martins M,Rosa A,Guedes LC,et al. Convergence of miRNA expression profiling,α-synuclein interacton and GWAS in Parkinson’s disease[J]. PLoS One,2011,6(10):e25443.

[17]Leung LY,Chan CP,Leung YK,et al. Comparison of miR-124-3p and miR-16 for early diagnosis of hemorrhagic and ischemic stroke[J]. Clin Chim Acta,2014,433:139-144.

[18]Martinez B,Peplow PV. Blood microRNAs as potential diagnostic markers for hemorrhagic stroke[J]. Neural Regen Res,2017,12(1):13-18.

[19]Li P,Teng F,Gao F,et al. Identification of circulating microRNAs as potential biomarkers for detecting acute ischemic stroke[J]. Cell Mol Neurobiol,2015,35(3):433-447.

[20]Modak JM,Roy-O’Reilly M,Zhu L,et al. Differential microribonucleic acid expression in cardioembolic stroke[J]. J Stroke Cerebrovasc Dis,2019,28(1):121-124.

[21]Zampetaki A,Willeit P,Tilling L,et al. Prospective study on circulating microRNAs and risk of myocardial infarction[J].?J Am Coll Cardiol,2012,60(4):290-299.

[22]Xu W,Huang L,Xie B,et al. Serum microRNA-4297 is a sex-specific predictive biomarker of glioma grade and prognosis[J].?Front Neurol,2022,13:888221.

[23]Poredo? P. Interrelationship between venous and arterial thrombosis[J].?Int Angiol,2017,36(4):295-298.

相似文献/References:

[1]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
　Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[2]马韵之 李剑 周鹏.糖尿病心肌病血清生物标志物研究进展[J].心血管病学进展,2021,(5):392.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.002]
　Serum Biomarkers of Diabetic Cardiomyopathy.[J].Advances in Cardiovascular Diseases,2021,(5):392.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.002]
[3]王梓良 何一秀 林伟力 张再磊 褚银平.单纯左心耳干预预防心源性脑卒中的研究进展[J].心血管病学进展,2021,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
　WANG ZiliangHE YixiuLIN WeiliZHANG ZaileiCHU Yinping.Prevention of Cardiogenic Stroke by Simple Intervention of Left Atrial Appendage[J].Advances in Cardiovascular Diseases,2021,(5):1007.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[4]杨珂欣 李星辉 肖晨朦 姚晓涛 林萌 蔡佳.间充质干细胞来源外泌体改善心肌纤维化的研究进展[J].心血管病学进展,2022,(12):1123.[doi:10.16806/j.cnki.issn.1004-3934.20.10.015]
　YANG Kexin LI Xinghui XIAO ChenmengYAO XiaotaoLIN MengCAI Jia.Improving Myocardial Fibrosis by Exosome Derived from Mesenchymal Stem Cell[J].Advances in Cardiovascular Diseases,2022,(5):1123.[doi:10.16806/j.cnki.issn.1004-3934.20.10.015]
[5]马艺萍 袁玉娟 艾力菲热·艾海提 马清玉 阿卜拉江·艾合麦提 穆叶赛·尼加提.内皮细胞微粒miRNA在急性心肌梗死中的研究进展[J].心血管病学进展,2023,(6):557.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.017]
　Ma Yiping,Yuan Yujuan,Ailifeire·Aihaiti,et al.Endothelial Microparticles miRNA in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2023,(5):557.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.017]

更新日期/Last Update: 2024-06-28